Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees

Bosslet

Frank Herman Bosslet, Rexbach DE

Patent application number	Description	Published
20110239980	Cover For A Diesel Particulate Filter	10-06-2011

Klaus Bosslet, Berlin DE

Patent application number	Description	Published
20080206201	Recombinant Newcastle Disease Virus - The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding proteins belong to the following group: A natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or a modified version of it, a peptide-ligand, an antibody molecule and derivatives thereof or antibody-like molecules like ankyrin repeat molecules or derivatives thereof.	08-28-2008
20090081207	High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity - The present invention relates to recombinant human or humanized polypeptides which bind to α5β1 integrin with high affinity and blocking function. Further, diagnostic and pharmaceutic applications of the potypeptides are disclosed.	03-26-2009
20100183505	IMMUNOCONJUGATE FOR HUMAN CD66 FOR THE TREATMENT OF MULTIPLE MYELOMA AND OTHER HAEMATOLOGICAL MALIGNANCIES - The present invention relates to the use of radioimmunoconjugates for the treatment of haematological malignancies, particularly multiple myeloma.	07-22-2010
20110020282	RECOMBINANT NEWCASTLE DISEASE VIRUS - The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding proteins belong to the following group: A natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or a modified version of it, a peptide-ligand, an antibody molecule and derivatives thereof or antibody-like molecules like ankyrin repeat molecules or derivatives thereof.	01-27-2011

Klaus Bosslet, Marburg DE

Patent application number	Description	Published
20090246132	Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof - The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.	10-01-2009